Anhedonia is a core feature of several psychiatric disorders but its biological underpinnings are 2 poorly understood. We performed a genome-wide association study of anhedonia in 375,275 UK 3 Biobank participants and assessed for genetic correlation between anhedonia and neuropsychiatric 4 conditions (major depressive disorder, schizophrenia, bipolar disorder, obsessive compulsive 5 disorder and Parkinson's Disease). We then used a polygenic risk score approach to test for 6 association between genetic loading for anhedonia and both brain structure and brain function. This 7 included: magnetic resonance imaging (MRI) assessments of total grey matter volume, white matter 8 volume, cerebrospinal fluid volume, and 15 cortical/subcortical regions of interest; diffusion tensor 9 imaging (DTI) measures of white matter tract integrity; and functional MRI activity during an 10 emotion processing task. We identified 11 novel loci associated at genome-wide significance with 11 anhedonia, with a SNP heritability estimate (h 2 SNP) of 5.6%. Strong positive genetic correlations 12 were found between anhedonia and major depressive disorder, schizophrenia and bipolar disorder; 13 but not with obsessive compulsive disorder or Parkinson's Disease. Polygenic risk for anhedonia was 14 associated with poorer brain white matter integrity, smaller total grey matter volume, and smaller 15 volumes of brain regions linked to reward and pleasure processing, including nucleus accumbens, 16 caudate and medial frontal cortex. In summary, the identification of novel anhedonia-associated loci 17 substantially expands our current understanding of the biological basis of anhedonia and genetic 18 correlations with several psychiatric disorders confirm the utility of this trait as a transdiagnostic 19 marker of vulnerability to mental illness. We also provide the first evidence that genetic risk for 20 anhedonia influences brain structure, particularly in regions associated with reward and pleasure 21 processing. 22
Introduction
1 Anhedonia refers to reduced capacity to experience pleasure in situations that individuals would 2 normally enjoy. It constitutes a core symptom of several neuropsychiatric disorders, particularly 3 major depressive disorder (MDD), schizophrenia, bipolar disorder and obsessive compulsive disorder 4 (OCD), as well as Parkinson's Disease (PD) [1] [2] [3] [4] . Along with a direct negative association with quality of 5 life and subjective wellbeing, anhedonia is associated with multiple negative health-related 6 behaviours, including smoking, illicit drug use, and lower physical activity, even in the absence of 7 psychiatric disorder 5, 6 . In line with a Research Domain Criteria (RDoC) perspective 7 , anhedonia can 8 be measured and studied as a dimensional psychopathological trait. 9
Anhedonia has been closely linked to the function and structure of reward circuitry in the brain 10 (primarily frontal, striatal and limbic regions). These neurobiological associations are consistent with 11 the view that anhedonia reflects dysfunction in reward processing 8, 9 . Measures of anhedonia have 12 been associated with altered functional activity during reward-based tasks within frontal cortical 13 regions (medial frontal cortex) and subcortical striatal regions (caudate and putamen) 10 , and with 14 reduced volumes in a similar set of frontal and striatal regions 11, 12 . Anhedonia is also associated with 15 reduced white matter integrity 13, 14 . 16 The genetic underpinnings of anhedonia are largely unknown. Several GWAS of disorders where 17 anhedonia is a feature have been reported, such as MDD and schizophrenia 15, 16 . However, to date 18 only small underpowered GWAS studies of anhedonia have been published. A study of 759 patients 19 with MDD identified 18 SNPs associated with an 'interest-activity' measure of anhedonia 17 . The 20 largest study to date is a mega-analysis of three studies of young people from the UK and Sweden, 1 with a total sample size of 6579; a single locus was associated with anhedonia in the discovery 2 sample, but not in the replication sample 18 . A Finnish study examined genetic associations with 3 physical and social anhedonia, as assessed with the Chapman scales, 19 in 3820 individuals but no 4 genome-wide significant loci were identified 20 . Genetic loci associated with symptoms of anhedonia 5 have therefore not yet been reliably identified in large clinical or general population samples 21 , and 6 association tests of genetic risk for anhedonia with brain structure and function have not yet been 7 performed. 8
Here we report a large GWAS of anhedonia within the UK Biobank cohort. We also use a polygenic 9 risk score (PRS) approach to assess whether genetic loading for anhedonia is associated with brain 10 structure and brain function. 11
Methods 1 UK Biobank sample 2 UK Biobank is a large cohort of over half a million UK residents, aged between 39 and 73 years at 3 baseline assessment 22 . The cohort was designed to assess how genetic, environmental and 4 lifestyle factors influence a range of morbidities in middle and older age. Baseline assessments 5 occurred over a 4-year recruitment period (from 2006 to 2010) across 22 UK centres. These 6 assessments covered a wide range of social, cognitive, lifestyle and physical health measures. 7
Informed consent was obtained from all participants, and this study was conducted under generic 8 approval from the NHS National Research Ethics Service (approval letter dated 13 May 2016, Ref 9
16/NW/0274) and under UK Biobank approvals for application #6553 'Genome-wide association 10 studies of mental health' (PI Smith). 11
Genotyping, imputation and quality control 12
In March 2018 UK Biobank released genetic data for 487,409 individuals, genotyped using the 13 Affymetrix UK BiLEVE Axiom or the Affymetrix UK Biobank Axiom arrays (Santa Clara, CA, USA), 14 which have over 95% of content in common 23 . Pre-imputation quality control, imputation (both 15 1000Genomes and HRC Reference Panels) and post-imputation cleaning were conducted centrally 16 by UK Biobank (described in the UK Biobank release documentation, please see URLs in appendix for 17 details). 18
Phenotyping 19 As part of the comprehensive baseline assessment participants were asked: "Over the past two 20 weeks, how often have you had little interest or pleasure in doing things?" (Data field 2060). 21
Respondents could choose from the following answers: "not at all"; "several days"; "more than half 22 the days"; and "nearly every day". These responses were coded as 0, 1, 2 and 3 respectively. This 23 question on anhedonia is derived from the Patient Health Questionnaire-9 (PHQ-9), a well-validated 24 screening instrument for MDD 24 . To maximise numbers available for downstream magnetic 1 resonance imaging (MRI) analyses, we excluded from the primary GWAS those participants with any 2 available MRI data. Additional exclusion criteria for the GWAS included individuals in whom: over 3 10% of genetic data were missing; self-reported sex did not match genetic sex; sex chromosome 4 aneuploidy was reported; where heterozygosity value was a clear outlier; and participants not of 5 European ancestry. 6
Genetic association and heritability 7
Genetic association with the measure of anhedonia was performed using BOLT-LMM 25, 26 , which 8 accounts for population structure and sample relatedness by including a genetic relatedness matrix 9 within the models. Models were further adjusted for age, sex and genotyping array. SNPs included in 10 the analysis were filtered by MAF > 0.01, Hardy-Weinberg Equilibrium p > 1x10 -6 , and imputation 11 score > 0.3. BOLT-LMM was also used to provide a SNP-heritability estimate and an estimate of λ GC . 12
Genetic correlations 13
Linkage Disequilibrium Score Regression (LDSR) 27 was carried out using LDSC on GWAS summary 14 statistics from several published studies, to obtain genetic correlations with psychiatric disorders 15
where anhedonia is known to be a feature (MDD, schizophrenia, bipolar disorder and OCD), as well 16
as Parkinson's Disease. 17
Polygenic risk score generation 18
Polygenic risk scores (PRS) were created using LDpred 28 . LDpred differs from the more common 19 pruning and threshold (P&T) PRS because it generates a single risk score for the trait of interest 20 derived from as many loci as possible. A training set was created to obtain the LD structure by using 21 1000 unrelated Biobank participants who had passed the same genetic QC as those used in the 22 GWAS (but who were excluded from the GWAS because they did not respond to the anhedonia 23 question and had not provided brain imaging data). These training data were then used for the 24 construction of anhedonia PRS in those participants for whom brain imaging data were available.
Brain imaging variables 1
A number of structural and functional brain MRI measures have been made available by UK Biobank 2 as Imaging Derived Phenotypes (IDPs) 29 . These measures are: total volume (mm 3 ) of brain grey 3 matter, white matter and cerebrospinal fluid (CSF), each normalised for head size; volumes (grey 4 matter or total) of 15 cortical and subcortical regions of interest (ROIs); diffusion tensor imaging 5 (DTI) measures of white matter integrity (fractional anisotropy (FA) and mean diffusivity (MD)); and 6 functional MRI activity during an emotion processing task (the Hariri face shape task) 30 in an 7 amygdala mask and group-defined mask consisting of occipito-temporal and amygdala regions. For a 8 more detailed description of these variables, and for details of MRI acquisition and pre-processing 9 and IDP selection, please see supplementary methods. 10
Polygenic risk score and brain imaging analyses 11 MRI data were available for 20,174 UK Biobank participants. PRS/MRI analyses were conducted in a 12 subset of 17,120 participants who had available MRI data and who were not included in the GWAS, 13 after exclusion of participants who did not meet genetic quality control criteria (n = 2,479) or who 14 self-reported a developmental or neurological disorder at either the baseline assessment or the 15 imaging visit (n = 575) (please see Table S1 for exclusions). For each MRI outcome, data points with 16 values more than 3 standard deviations from the sample mean were excluded. 17 Models were adjusted for age at MRI visit, (age at MRI) 2 , sex, genotype array, the first eight genetic 18 principal components, and lateral, transverse and longitudinal scanner position covariates. Total 19 tissue volume measures (total grey matter, white matter and ventricular CSF volumes) were 20 normalised for head size prior to adjustment for the above covariates. ROI analyses were 21 additionally adjusted for total brain volume (calculated by summing total grey matter, white matter 22 and ventricular cerebrospinal fluid (CSF) volume); and fMRI analyses were also adjusted for head 23 motion during the emotion processing task. False discovery rate (FDR) correction was applied 31, 32 . 24 Results 1 Demographics 2
The GWAS was performed on 375,724 UK Biobank participants, of whom 203,322 (54.1%) were 3 female. The age of the sample ranged from 39 to 73 and the mean age was 57 years (S.D. = 8.01). In 4 response to the anhedonia question, 299,232 (79.64%) answered "not at all"; 60,212 (16.0%) 5
reported "several days"; 9,405 (2.5%) reported "more than half the days" and 6,876 (1.8%) reported 6 "nearly every day". 7 MRI analyses were conducted in 17,120 participants, 52.4% (8,978) of whom were female. The mean 8 age (at the time of MRI) of these participants was 62.7 years (S.D. = 7.46; range = 45-80 years). Of 9 the 16,783 participants with available MRI data who answered the anhedonia question, 13,810 10 (82.3%) responded "not at all", 2,469 (14.7%) reported feelings of anhedonia for "several days", 297 11
(1.8%) for "more than half the days", and 207 (1.2%) "nearly every day". 12
Genome-wide association study findings 13 GWAS results are presented as a Manhattan plot in Figure 1 , and details of genome-wide significant 14 loci are provided in Table S2 . In all, there were 1100 SNPs that were genome-wide significant (p < 5 x 15 10 -8 ), and, of these, 11 represented independent lead SNPs at separate loci on 9 different 16 chromosomes (Table S2 ; Figures S1-S11). An independent signal was defined as the region of r 2 > 0.1 17 within a 500MB window from the most significant SNP below genome-wide significance. 18 Some inflation of the GWAS results was observed (λ GC = 1.15), however considering the sample size 19 this is expected to have had a negligible impact on findings. There was evidence for a polygenic 20 component (LDSR intercept = 1.03, S.E. = 0.005) and no evidence for undue inflation of the test 21 statistics due to unaccounted population stratification. 22
Genetic correlations 1
Using LDSR we assessed whether genetic predisposition to anhedonia overlapped with that for 2 several psychiatric disorders or traits. Anhedonia had significant genetic correlation with MDD (r g 3 0.77), schizophrenia (r g 0.28) and bipolar disorder (r g 0.12) but not with OCD or Parkinson's Disease 4 (Table 1) . 5
PRS and brain MRI structural and functional outcomes 6
Associations between PRS for anhedonia and total brain tissue volumes are presented in Table S3 . 7
Greater polygenic risk for anhedonia was associated with lower total grey matter volume, but not 8 with total white matter volume or with total ventricular CSF volume. 9
Associations were then assessed between PRS for anhedonia and volumes of 15 cortical and 10 subcortical regions of interest (ROIs were derived a priori from meta-analysis and literature review; 11 please see Table S4 and Supplementary Methods). Greater genetic risk score for anhedonia was 12 associated with smaller volumes for nucleus accumbens, insular cortex, medial frontal cortex, 13 orbitofrontal cortex, middle frontal gyrus and anterior temporal fusiform cortex. No significant 14 associations were observed for the remaining nine ROIs. The locations of the ROIs showing 15 significant association with the PRS are displayed in Supplementary Figure S12 , and a point-range 16 plot showing the association evidence for ROI volumes is displayed in Figure 2A . 17
In subsequent analyses of association with white matter integrity, greater PRS for anhedonia was 18 associated with a higher mean diffusivity (MD) ( Table S5) but no association was observed between 19 PRS for anhedonia and fractional anisotropy (FA). PRS associations were assessed with 15 individual 20 white matter tracts (bilateral tracts were combined in the same models and models were adjusted 21 for hemisphere; see Supplementary Methods, Supplementary Table S6 and S7). Higher PRS for 22 anhedonia was associated with lower FA in five of the fifteen tracts (anterior thalamic radiation, 23 forceps major, forceps minor, medial lemniscus, posterior thalamic radiation) ( Figure 2B ). Higher PRS 24 for anhedonia was also associated with higher MD in 12 of the 15 tracts (all apart from forceps major, medial lemniscus and parahippocampal part of cingulum) ( Figure 2C ). There was no 1 association between PRS for anhedonia and functional MRI activity during the emotion-processing 2 task (median Blood Oxygen Level Dependent signal for the face vs. shape contrast) (Table S8) . 3 4 Discussion 1 These analyses represent the largest genetic association study of anhedonia performed to date. We 2 identified eleven genetic loci associated with anhedonia in the UK general population. Within each 3 associated region there were a number of genes that could have a functional impact on anhedonia 4 and the pleasure cycle (considered in detail below). Consistent with an RDoC approach focusing on 5 transdiagnostic traits, we found strong genetic correlations between anhedonia and MDD, 6 schizophrenia and bipolar disorder, but not between anhedonia and OCD or Parkinson's Disease. 7
Despite the lack of correlation with Parkinson's Disease, several of the loci identified in our GWAS 8 include genes with known association with Parkinson's Disease (see below). We also report the first 9 investigation of associations between genetic loading for anhedonia and both brain structure and 10 brain function. 11
Genes within anhedonia-associated loci 12
Within the chromosome 1 locus there are multiple RGS genes, most notably RGS1 and RGS2, 13 encoding regulators of G-protein signalling that show prominent expression in the brain 33 . RGS2 has 14 previously been identified as a modulator of LRRK2 34 expression, a gene known to be a genetic cause 15 of Parkinson's Disease. RGS2 has also been associated with symptom severity in schizophrenia 35 and 16 lower expression of RGS2 may be related to depression-like behaviours in animal models 36 . 17 EPHB1 on chromosome 3 encodes an ephrin receptor tyrosine kinase identified in a GWAS of 18 antidepressant response 37 , and is associated with symptoms of schizophrenia in Chinese Han 19 populations 38 , and with susceptibility to Parkinson's Disease 39 . 20 At the more centromeric locus on chromosome 11, GRM5 encodes a metabotropic glutamate 21 receptor that has been extensively studied in relation to MDD 40, 41 and schizophrenia 42, 43 . 22 Assessments in mice have also found that agonists of GRM5 attenuate Parkinsonian motor deficits 23 via striatal dopamine depletion 44 . The Genotype Tissue Expression (GTEx) database 33 shows 24 prominent expression of GRM5 in the brain, especially within the nucleus accumbens, a region with 1 a major role in the prediction of reward 45, 46 . As discussed further below, it is of note that we found 2 that greater PRS for anhedonia was associated with smaller volume of the nucleus accumbens. 3
Another likely candidate gene at this chromosome 11 locus is DISC1FP1. DISC1 (Disrupted in 4 Schizophrenia 1), a gene located on chromosome 1, is part of a chromosome 1:11 translocation that 5 increases risk of schizophrenia, schizoaffective disorder and bipolar disorder 47 . DISC1FP1 is disrupted 6 by this translocation, impacting on both intracellular NADH oxidoreductase activities and protein 7 translation 48 . 8
At the more telomeric locus on chromosome 11, NCAM1 (neural cell adhesion molecule 1) has been 9 implicated as a potential link between depressive symptoms and brain structure 49 , 10 specifically decreased FA. NCAM1 has been reported to be present at increased levels in the 11 amygdala 33 , another brain region associated with the pleasure cycle, in depressed subjects 50 . 12
However, we did not find any association between PRS for anhedonia and either amygdala volume 13 or functional activity in the amygdala during an emotion processing task. It is possible that NCAM1 14 may exert its effects via expression in other brain regions. 15
Another gene of interest at this second chromosome 11 locus is DRD2, encoding the dopamine D2 16
receptor. There is an extensive literature on the importance of DRD2 for the psychopharmacology of 17 both schizophrenia and MDD 51,52 . 18
The chromosome 12 locus contains only LOC and LINC genes. These encode different classes of 19 functional RNA but little is known about their function beyond possible post-transcriptional 20 regulation of other gene products. 21
The more centromeric locus on chromosome 14 contains PRKD1, which encodes a serine/threonine-22 protein kinase identified in a GWAS of schizophrenia 16 . The more telomeric locus on chromosome 23 1 tissues, including neurons. SLC8A3 may also play a role in Parkinson's Disease 53 . 2 ISLR2 on chromosome 15 is involved in neurodevelopment 54 but its role in psychiatric and 3 neurological traits is not well characterised. Another candidate gene within this locus, NRG4, 4 encodes a neuregulin protein that activates type-1 growth factor receptors. Recent work has shown 5 that NRG4 acts a regulator of the growth and elaboration of pyramidal neuron dendrites in the 6 developing neocortex 55 . Pyramidal neurons have been directly implicated in the pathophysiology of 7 schizophrenia 56 . 8
Finally, on chromosome 18, DCC (the most significant hit) encodes a netrin 1 receptor with a role in 9 axon guidance, and has been previously reported to be associated with anhedonic phenotypes in 10 mice and humans 57 and potentially with schizophrenia pathogenesis 58 . We have previously identified 11 DCC in GWAS of mood instability 59 , suicidality 60 and multisite chronic pain 61 . 12
Brain Structure and function 13
Our findings on the relationship between genetic loading for anhedonia and brain structure and 14 function are of considerable interest. Greater levels of anhedonia, in healthy and clinical 15 populations, have been linked to altered functional activity (and less consistently to reduced 16 volume) in frontal/striatal regions involved in reward or pleasure processing 10-12, 62-66 . The regions 17 most consistently implicated include nucleus accumbens, caudate, putamen, medial frontal cortex 18 and orbitofrontal cortex. 19
We found that increased genetic risk for anhedonia was associated with smaller volumes of nucleus 20 accumbens, medial frontal cortex and orbitofrontal cortex (Figure 2A; Supplementary Figure 1) . 21
Nucleus accumbens is involved in reward value and pleasure processing 64, 67 . Orbitofrontal cortex is 22 involved in representation of reward value and social reward dependence 65, 68 , and medial frontal 23 cortex has been linked to pleasure processing 64 . These cortical/subcortical volume findings are 24 therefore consistent with an association between genetic risk for anhedonia and abnormal 1 reward/pleasure processing 67 . 2 Increased genetic risk for anhedonia was also associated with smaller volumes of insular cortex 3 (associated with emotion processing 69 ) and fusiform cortex. Most ROIs in our analysis were selected 4 on the basis that they were associated with smaller volumes in MDD versus healthy controls in the 5 most recent MDD brain structure meta-analysis 70 . Our findings are consistent with two scenarios: 6 either genes for anhedonia partly mediate the association between the ROI volumes and MDD, or 7 these genes exhibit horizontal pleiotropy and affect both phenotypes via separate mechanisms. 8
Consistent with our finding of widespread associations of genetic risk for anhedonia with 9 cortical/subcortical volumes, we also found an association with reduced total grey matter volume, 10 adjusted for head size. 11
Evidence of reduced white matter integrity (FA) in several tracts in individuals scoring higher on 12 measures of anhedonia has been reported 14, 71 . We found that higher values for the anhedonia PRS 13 were associated with higher MD (reflecting poorer white matter integrity), both in a general factor, 14 and in most individual tracts. Several tracts also showed reduced FA. 15
We did not, however, find any association between PRS for anhedonia and functional brain activity. 16 UK Biobank ROIs were selected based on average responses during an emotion processing task; it is 17 therefore plausible that effects would emerge with the use of a reward processing task, or by 18 applying whole-brain voxel-wise analyses, to include further reward/pleasure processing regions. 19
Strengths and limitations 20
This study is the largest GWAS of anhedonia to date, and substantially contributes new knowledge 21 on the biology of this important transdiagnostic symptom. We conducted analyses within a large 22 population-based cohort. Our primary analysis included individuals with mental health histories, but 23 these represent only a small proportion of a total sample, which is an order of magnitude larger than 24 any previous study of this kind. Subclinical anhedonia is common, and associated with increased risk 1 of later mental illness 72 . This idea is reinforced by the significant genetic correlations with other 2 psychiatric disorders. Additionally, we used a multi-level ordinal phenotype, resulting in more power 3 to detect associations than with the more common dichotomised ('non-anhedonic' versus 4 'anhedonic') analyses 73 . Identification of loci associated with population-level anhedonia may be 5 important from a precision medicine perspective, for example in terms of developing stratified 6 medicine approaches to identify individuals at high-risk of developing psychiatric disorders. 7
Notably, however, the UK Biobank cohort has a degree of selection bias. In general, volunteers are 8 typically healthier and of higher socioeconomic status and education level than the general 9 population 74 , which may have led to under-representation of predisposing alleles in the higher levels 10 of the anhedonia outcome variable. This bias may have been further amplified in the sub-sample 11 who attended the imaging visit (these participants also showed somewhat reduced likelihood of 12 reporting recent symptoms of anhedonia). Therefore, it is plausible that the strength of reported 13 associations may be an underestimate of the true population value, and there may also be an 14 inflated type 2 error rate. 15
The measure of anhedonia employed here was a question from a depression screening instrument, 16 the PHQ-9, assessing frequency of anhedonia within the past two weeks. This item therefore 17 measures state anhedonia at a single time point, and could be influenced by environmental factors, 18 such as season or current health status 75, 76 . However, we have assumed here that despite transient 19 environmental and physical factors, individuals who are prone to trait anhedonia will be more likely 20 to report higher frequency of anhedonia at any given time point, and it seems likely that a recent 21 anhedonia phenotype will be enriched for individuals with stronger genetic predisposition compared 22 to a similar phenotype based on lifetime incidence. In line with this assumption, the anhedonia item 23 of the PHQ-9 at a single time point has shown utility in predicting longitudinal brain structural 24 change 77 . 25
The GWAS treated the ordinal responses to the frequency of anhedonia question as linear. This 1 approach is likely to have had a minimal impact on the BOLT-LMM GWAS results. Although the 2 distance between points on the anhedonia scale is not evenly spaced, each point can reasonably be 3 considered to be higher than the point before it. 4
The anhedonia measure did not enable determination of specific anhedonia subtypes. Existing 5 validated instruments typically divide anhedonia into physical and social subscales 19 , or into 6 anticipatory versus consummatory components of pleasure 78 . Future studies using more detailed 7 anhedonia scales may be of use in examining the extent of genetic overlap between anhedonia 8 subtypes. 9
Conclusion 10
We report the largest GWAS to date of anhedonia, a common symptom associated with several 11 psychiatric disorders. We identified 11 novel genetic loci and our findings indicate substantial 12 genetic overlap between anhedonia and several psychiatric disorders including MDD, schizophrenia 13 and bipolar disorder. PRS analyses revealed association between genetic loading for anhedonia and 14 smaller volumes of several brain regions, and poorer white matter integrity. Taken together, these 15 findings provide important insights into the neurobiology of an important but under-studied 16 psychiatric symptom and strongly support the proposition that genetic predisposition to anhedonia 17 may influence brain structure and function. 18 Table 1 Genetic correlations of mood instability with psychiatric phenotypes. rg = genetic correlation 7 with mood instability, S.E. = standard error of the genetic correlation, Z = the test statistic, p = the p 8 value, q the False discovery rate corrected p value. MDD = major depressive disorder, PTSD = post-9 traumatic stress disorder. 10 11 1 Figure 2 . Plots of associations (regression coefficients and 95% confidence intervals (CI)) between 2 polygenic risk for anhedonia and A) regional volumes of cortical/subcortical ROIs; B) tract-specific 3 fractional anisotropy; and C) tract-specific mean diffusivity. 4 5
